She is taking on the pharmaceutical and for-profit medical industries by championing legislation to lower the cost of healthcare and prescription drugs.
Champion legislation to lower the cost of healthcare and prescription drugs.
Occurrences
Evidence
“As Congresswoman, Delia is a champion for getting health care costs down... She is taking on the pharmaceutical and for-profit medical industries by championing legislation to lower the cost of healthcare and prescription drugs.”
HB 3596 lists Delia C. Ramirez as a House co-sponsor and became Public Act 102-0490. The bill required electronic prescribing for controlled substances, part of reducing misuse and improving prescription oversight.
HB 3630 regulates pharmacy benefit managers and says a PBM may not require a patient to pay more than the lesser of cost-sharing or cash price, and may not restrict access to cheaper alternatives.
Her member record shows HB3630, INS-PHARMACY BENEFIT MANAGERS, and HB3493, DHFS-COVERAGE-NONCITIZENS, among her sponsored bills, along with HB3596 where she was added as co-sponsor.
The report notes Democratic work on lowering prescription drug costs and cites H.R. 4895, the Lowering Drug Costs for American Families Act, which would extend IRA drug price negotiation savings to private coverage.
Assessments
The promise was framed as championing legislation to lower healthcare and prescription-drug costs, not guaranteeing full cost reductions. The evidence shows Ramirez supported and sponsored relevant health coverage and prescription-drug affordability legislation, including pharmacy benefit manager regulation and prescription-related measures, which aligns with the legislative-championing portion of the pledge. However, the record provided does not establish that she delivered broad federal healthcare or prescription-drug cost reductions as a final enacted outcome during her congressional term, and some evidence predates her federal office. This supports a partial fulfillment with clear effort rather than full delivery.